Скачать или смотреть Cannabis Innovation Center at Rabin Medical Center

http://cannabis-innovationcenter.com/

Cannabis Innovation Center (CIC)
the CIC is a group of startup companies in the Biotech space with an emphasis on Cannabis. We have an active front in almost every aspect with a clear advantage in the pharma and drug development with the exception of agriculture (we do not touch any agriculture related projects).
As you will see below in more details, the CIC includes a variety of interesting companies, so far including Stero, CannaLean, CannaMore, IcBD, NeuroSeed, BioSeedXL & CannaDu.

Our Strong Clinical partner:
Our main advantage is the ground breaking partnership and support of one of our shareholders, MOR Research Applications, the commercializing arm of CLALIT HEALTH SERVICES, the 2nd largest HMO in the world, with over 4.5M members, Operating 14 full scale hospitals specializing in all fields of medicine, over 2000 community clinics, over 9000 employed physicians.

Our IP-based pharma Companies:

STERO, a clinical-stage company committed to the research and development of novel and improved Cannabidiol (CBD) based treatment solutions that will potentially benefit millions of patients by reducing the side effects and the need of steroid therapy .
STERO’s extremely wide coverage patent (CBD from any source, in any combination, any dosage, in any delivery system, all for more than 130 diseases by name) was Issued in the US on August 2018 and is pending in main countries around the world. Stero currently has 2 ongoing phase 2a clinical trials in Crohn's disease and in chronic Urticaria (Hives), pursuing the FDA drug route.
As we are an IP-based steroid sparing treatment, meant for:
1. Enhance the therapeutic effect of a steroid treatment
2. Lower the dosage needed for steroids thus reducing their side-effects
3. Allowing refractory patients respond to their steroid treatments

CannaLean, is committed to the research and development of a novel proprietary formulation of Cannabidiol (CBD) and Chitosan that will potentially benefit millions of patients suffering from Dyslipidemia, an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids). CannaLean has successfully completed various in vivo and pre-clinical studies showing a significant decrease in cholesterol/triglyceride blood levels, demonstrating the potential clinical effect of the novel patent-protected formulation. Thanks to its unique formulation CannaLean can initiate sales while still working in parallel on the drug development in FDA route.

IcBD, is committed to the research and development of a novel proprietary formulation of Cannabidiol (CBD) and Chitosan for treatment of Inflammatory Bowel Diseases (IBD).
IcBD is based on observation of various in vivo, pre-clinical and clinical studies demonstrating the potential and clinical effect of the novel patent-protected formulation. IcBD plans on the drug development in FDA route.
With its patent-protected enema formulation plans to commence phase 2a clinical trials, starting with Ulcerative colitis on 2020.

CannaMore was founded in 2018, with all the experience from the above, and is headquartered in Israel, the leading pioneer of cannabis research and development.
CannaMore is a pre-clinical and clinical stage research platform company committed to the development of novel and improved cannabis-based treatment options that will potentially benefit millions of patients worldwide.
CannaMore already has 2 ventures under development in the fields of Lung diseases and Neuropathy diseases, planned for clinical trials in 2020-2021.